La qualité des enregistrements au cœur de cette mise en demeure...
Dans cette récente "Warning Letter", la FDA américaine mentionne plusieurs écarts importants dans la gestion des enregistrements réglementés : 1. Failure to maintain complete data derived from all laboratory tests conducted to ensure compliance with established specifications and standards. Your firm lacked accurate raw laboratory data records for API batches shipped by your firm. The inspection revealed that batch samples were retested until acceptable results were obtained. In addition, your quality control (QC) laboratory failed to include complete data on QC testing sheets. Failing or otherwise atypical results were not included in the official laboratory control records, not reported, and not investigated... 2. Failure to investigate and document out-of-specification results... Your management failed to prevent the practices of product sample retesting without investigation, and rewriting and/or omission of origina...